Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.51 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21056123 | 1.00 | TP53 (0.62) | TP53KMT2AMEN1RAB9ABLM | |
| SCHEMBL2420009 | 0.84 | ALDH1A1 (0.62) | RAB9AKDM4ERECQLHSD17B10ALDH1A1 | |
| SCHEMBL21056133 | 0.84 | ALDH1A1 (0.62) | RAB9AKDM4ERECQLHSD17B10ALDH1A1 | |
| SCHEMBL13653042 | 0.78 | MAPT (0.62) | KMT2AMEN1KDM4ERECQLHSD17B10 | |
| SCHEMBL2420041 | 0.75 | MEN1 (0.48) | TP53KMT2AMEN1RAB9ABLM | |
| SCHEMBL21056112 | 0.75 | MEN1 (0.48) | TP53KMT2AMEN1RAB9ABLM | |
| SCHEMBL11616443 | 0.75 | ALDH1A1 (0.66) | KMT2AMEN1RAB9ABLMKDM4E | |
| SCHEMBL2419971 | 0.75 | MAPT (0.57) | KMT2AMEN1KDM4ERECQLHSD17B10 | |
| SCHEMBL28695916 | 0.73 | ALDH1A1 (0.76) | TP53KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL14920649 | 0.73 | MEN1 (0.56) | TP53KMT2AMEN1RAB9ABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723744-B1 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | DOMPE FARM SPA (IT) | 2026-03-18 | — | — | EP | claimed |
| EP-4706762-A2 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | Dompé farmaceutici SpA (IT) | 2026-03-11 | — | — | EP | claimed |
| EP-4308114-B1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | DOMPE FARM SPA (IT) | 2026-02-11 | — | — | EP | claimed |
| US-20240398731-A1 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | DOMPE' FARMACEUTICI S.P.A. (IT) | 2024-12-05 | — | — | US | claimed |
| EP-4397306-A1 | C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompe' Farmaceutici S.P.A. (IT) | 2024-07-10 | — | — | EP | claimed |
| US-20240180888-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | DOMPE' FARMACEUTICI SPA (IT) | 2024-06-06 | — | — | US | claimed |
| EP-4308114-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | Dompe' Farmaceutici SpA (IT) | 2024-01-24 | — | — | EP | claimed |
| WO-2022195017-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | DOMPE' FARMACEUTICI SPA (IT) | 2022-09-22 | — | — | WO | claimed |
| EP-4059497-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | Dompé farmaceutici S.p.a. (IT) | 2022-09-21 | — | — | EP | claimed |
| US-20200397725-A1 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | DOMPE' FARMACEUTICI S.P.A. (IT) | 2020-12-24 | — | — | US | claimed |
| EP-3723744-A2 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | Dompé farmaceutici S.p.A. (IT) | 2020-10-21 | — | — | EP | claimed |
| WO-2019115493-A2 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | DOMPE' FARMACEUTICI S.P.A. (IT) | 2019-06-20 | — | — | WO | claimed |
| EP-3498269-A1 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | Dompé farmaceutici S.p.A. (IT) | 2019-06-19 | — | — | EP | claimed |
| EP-1951663-B1 | (R)-ARYLKYLAMINO DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPÉ FARMACEUTICI S P A (IT) | 2016-07-20 | — | — | EP | claimed |
| US-8026367-B2 | (R)-arylalkylamino derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2011-09-27 | — | — | US | claimed |
| US-20090124664-A1 | (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-05-14 | — | — | US | claimed |
| EP-3723744-B1 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | DOMPE FARM SPA (IT) | 2026-03-18 | — | — | EP | disclosed |
| EP-4706762-A2 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | Dompé farmaceutici SpA (IT) | 2026-03-11 | — | — | EP | disclosed |
| US-20090124664-A1 | (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-05-14 | — | — | US | disclosed |
| WO-2007060215-A2 | (R)-ARYLKYLAMINO DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA S.P.A. (IT) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180888-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | C5AR1, C5AR2, C3AR1 | TP53 566/4885KMT2A 3353/4885MEN1 1465/4885 |
| US-20240398731-A1 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | C5AR2, C5AR1, C3AR1 | TP53 1698/4885KMT2A 4050/4885MEN1 3328/4885 |
| US-20090124664-A1 | (R)-Arylalkylamino Derivatives and Pharmaceutical Compositions Containing Them | C3AR1, C5AR1, CCR8 | TP53 3570/4885KMT2A 4790/4885MEN1 4749/4885 |
| US-20200397725-A1 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | C5AR2, C5AR1, C3AR1 | TP53 1698/4885KMT2A 4050/4885MEN1 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.